(DTIL) Precision BioSciences, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(DTIL) Precision BioSciences, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Precision BioSciences, Inc. 4P's Marketing Mix Analysis summarizes the company’s Product, Price, Place, and Promotion strategy and shows how these choices support positioning and growth; the page includes a real preview/sample of the analysis so you can assess style and content before buying. Purchase the full version to unlock the complete ready-to-use report.
Product
ARCUS genome editing platform
ARCUS is Precision BioSciences, Inc.’s core genome-editing engine for in vivo gene editing and potential one-time correction of disease-causing DNA. It underpins the Company’s pipeline and partnering strategy, including programs such as PBGENE-HBV. The platform’s value is its precision and repeatability, which are key for durable therapeutic effects.
PBCAR0191 Phase 1/2a
PBCAR0191 is Precision BioSciences, Inc.'s investigational allogeneic CAR T therapy in Phase 1/2a, being studied in adult patients with relapsed or refractory non-Hodgkin lymphoma and relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This pipeline asset reinforces Precision BioSciences, Inc.'s cancer-treatment focus and its push into off-the-shelf cell therapy. For Product strategy, it broadens the company's oncology reach without relying on a single tumor type.
PBCAR19B stealth cell
PBCAR19B is Precision BioSciences, Inc.’s anti-CD19 CAR T candidate built with a single-step gene edit, aiming to cut the risk of chromosomal abnormalities. The "stealth cell" design is meant to improve safety and T-cell performance in a 19-targeted program. In the Product mix, it is a differentiated, next-gen cell therapy asset rather than a broad platform.
PBCAR269A BCMA target
PBCAR269A is Precision BioSciences, Inc.'s allogeneic CAR T cell therapy for BCMA, aimed at relapsed or refractory multiple myeloma, a disease with about 35,000 new U.S. cases in 2024. It expands the pipeline beyond CD19 and fits a market where BCMA therapies have already won FDA approval and helped drive U.S. myeloma drug sales past $3 billion annually.
- BCMA target widens Precision BioSciences, Inc. reach
- Allogeneic design supports faster, off-the-shelf use
- Focuses on relapsed or refractory multiple myeloma
- Moves beyond CD19-only program concentration
Ex vivo allogeneic CAR T therapies
Precision BioSciences, Inc. treats ex vivo allogeneic CAR T as a platform, not one drug: donor T cells are edited outside the body with ARCUS gene editing, then given to patients to find and kill cancer cells. The allogeneic model can support off-the-shelf dosing, unlike autologous CAR T made from each patient’s own cells.
- Platform, not a single product
- Cells are edited ex vivo
- Allogeneic means donor-derived
- Goal: faster, scalable cancer targeting
Precision BioSciences’ ARCUS Platform Drives CAR T and Gene Editing
Precision BioSciences, Inc.’s Product mix centers on ARCUS, its gene-editing platform, plus ex vivo allogeneic CAR T assets that widen its reach across oncology and infectious disease. PBCAR0191, PBCAR19B, and PBCAR269A keep the pipeline focused on off-the-shelf cell therapy, while PBGENE-HBV extends the platform into one-time DNA correction.
| Asset | Role |
|---|---|
| ARCUS | Core editing engine |
| PBCAR0191 | CD19 CAR T |
| PBCAR19B | Next-gen CD19 CAR T |
| PBCAR269A | BCMA CAR T |
| PBGENE-HBV | HBV gene-editing program |
What is included in the product
Detailed Word Document
A concise, company-specific 4P’s analysis of Precision BioSciences, Inc.’s product, pricing, place, and promotion strategy.
Editable Excel File
Helps quickly clarify Precision BioSciences’ 4Ps, reducing analysis friction for faster stakeholder alignment.
Reference Sources
Cites primary industry reports, peer-reviewed studies, SEC filings, and benchmark datasets to speed due diligence and verify key Precision BioSciences claims.
Place
Durham North Carolina HQ
Precision BioSciences, Inc. is headquartered in Durham, North Carolina, anchoring its U.S. operations in the Research Triangle area. The site supports corporate leadership, research coordination, and partner management, which helps keep development and business teams close to biotech talent and institutions in a metro of about 285,000 people. This HQ gives the company a central base for decision-making and collaboration.
Clinical-stage U.S. development
Precision BioSciences, Inc. uses a clinical-stage U.S. development model, so its “place” is research hospitals, trial sites, and regulated FDA pathways, not retail channels. Its lead programs move through Phase 1/2 studies in the United States, which means access is driven by investigator sites and patient enrollment rules. This setup keeps distribution tight and clinical, with value created only after trial data support each next step.
Partner-led commercialization
Precision BioSciences, Inc. uses alliance partners to develop and sell its programs, which lets it reach markets beyond its small internal team. Servier is the key partner for its allogeneic CAR T work, tied to an agreement that can deliver up to $1.2 billion in milestones plus tiered royalties. This partner-led model lowers commercial spend while widening access.
Trial-site distribution model
Precision BioSciences, Inc. uses a trial-site distribution model, so its therapies reach patients only through clinical trial sites and investigator networks. That keeps delivery inside controlled study settings and makes the site network the main route to market. In its latest public filings, the Company reported a cash position of about $77.5 million at year-end 2025, supporting this site-led clinical buildout.
- Clinical trial sites are the main channel
- Patients get therapies in controlled settings
- Investigator networks drive trial access
- 2025 cash: about $77.5 million
Collaborative R and D network
Precision BioSciences, Inc. uses a partnership-based "Place" model for its collaborative R and D network, working with iECURE and Tiziana Life Sciences on selected programs. This extends scientific reach and lowers the need for a retail footprint, while also sharing development risk and operating access across programs.
- Partner-led access, not retail distribution
- iECURE and Tiziana Life Sciences support selected programs
- Broader scientific reach and operational footprint
Precision BioSciences Leans on Clinical Sites and Partners
Precision BioSciences, Inc. keeps "Place" tightly controlled: Durham HQ, U.S. trial sites, and partner networks, not retail channels. Its lead programs move through Phase 1/2 study sites, while Servier, iECURE, and Tiziana Life Sciences extend reach and share risk. Year-end 2025 cash was about $77.5 million, supporting this site-led model.
| Place factor | Data |
|---|---|
| HQ | Durham, North Carolina |
| Channel | Clinical trial sites |
| Partners | Servier, iECURE, Tiziana |
| 2025 cash | $77.5 million |
Preview Before You Purchase
Precision BioSciences, Inc. Reference Sources
The preview shown here is the actual Precision BioSciences 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises; it’s the complete, ready-to-use document with product, price, place, and promotion insights tailored to the company.
Promotion
Partnership announcements
Precision BioSciences uses partnership news as promotion, and its Servier, Tiziana Life Sciences, and iECURE agreements put 3 external names behind the ARCUS platform. These deals help validate the science and widen visibility with investors and researchers. In 2025, that kind of third-party backing mattered more than ad spend for a small biotech with limited commercial revenue.
Clinical trial updates
Phase 1/2a updates for PBCAR0191 keep Precision BioSciences, Inc. in the spotlight, because each clinical milestone can shift investor sentiment and partnering interest. Early trial progress in relapsed/refractory B-cell cancers signals development momentum and scientific relevance. In biotech, these updates are often the strongest promotion tool.
Investor relations disclosures
Precision BioSciences uses earnings releases, SEC filings, and corporate updates to share pipeline progress, cash position, and strategy. In its latest public reporting, that kind of disclosure is key for a company with a small-cap profile and a cash-intensive gene-editing pipeline, because investors track runway and clinical milestones closely. Clear updates keep the market aware and can move sentiment fast.
Scientific positioning
Precision BioSciences promotes ARCUS as its proprietary genome editing platform, built to target precise DNA cuts for genetic disease and cancer immunotherapy. The story is technology-led: in 2025, the company had 1 lead clinical program for chronic hepatitis B and 1 preclinical oncology focus, keeping the message centered on platform breadth and pipeline depth. That positioning helps frame Precision BioSciences, Inc. as a science-first biotech, not a drug seller.
- ARCUS = proprietary genome editing platform
- Focus: genetic disease and cancer immunotherapy
- 2025 pipeline: 1 clinical, 1 preclinical focus
Medical and research visibility
Precision BioSciences, Inc. uses medical and research visibility to reach clinicians, researchers, partners, and investors, not mass consumers. Its promotion leans on scientific credibility, with conference presentations and research updates doing most of the work. In FY2025, that made third-party validation and data readouts more important than broad ad spend.
- Targets clinicians and researchers
- Uses conference and data updates
- Builds trust through science
- Supports partner and investor outreach
ARCUS Advances on Data, Backed by Key Partners
Precision BioSciences, Inc. promotes ARCUS through data, not ads. In FY2025, 1 clinical program in chronic hepatitis B and 1 preclinical oncology focus kept the story tied to milestones, while partner names like Servier, Tiziana Life Sciences, and iECURE added outside validation.
| FY2025 signal | Value |
|---|---|
| Clinical programs | 1 |
| Preclinical focus | 1 |
| Key partners | 3 |
Price
No commercial product pricing
Precision BioSciences, Inc. had no approved commercial products in fiscal 2025, so it reported no retail product pricing. With a clinical-stage pipeline and no product sales, pricing is set by future reimbursement and partner deals, not by a public consumer price list.
Milestone-based collaboration economics
Precision BioSciences uses milestone-based collaboration economics to monetize value before product sales. Its Servier deal and other partnerships can bring upfront cash, development milestones, and commercial milestones, which is common in biotech before launch. In this model, partner payments often matter more than near-term product revenue.
Research and development funding
Research and development is the main “price” driver for Precision BioSciences, Inc., since value depends on clinical progress, not product tariffs. The company funds R&D through internal cash, collaboration payments, and financing, so capital needs directly shape dilution and runway. In biotech, one delayed trial can shift spend by millions, making funding discipline a core part of pricing.
Premium innovation value
Precision BioSciences, Inc. prices its "Premium innovation value" on ARCUS and allogeneic CAR T potential, not build cost. For a platform still driven by clinical readouts and partner interest, investor value is set by success odds, addressable patient pools, and timing of proof, so every data update can re-rate the story fast.
That means the market pays for future utility, not just today’s manufacturing economics. In biotech, a program with strong efficacy and safety can command far more value than its unit cost suggests, while weak trial data can compress valuation sharply.
Access through trials
Precision BioSciences, Inc. still prices its candidates through clinical studies, so patients access them at no standard market price. That keeps the cost inside trial budgets and away from commercial pharmacy channels. The key signal is simple: with 0 marketed therapies in this bucket, Precision BioSciences, Inc. is still a development-stage company, not a market-priced therapeutic seller.
- Clinical trials, not retail pricing
- Costs shift to study sponsors
- 0 commercial product sales here
Precision BioSciences: No Products, Just Milestone-Driven Value
Precision BioSciences, Inc. had 0 approved commercial products in fiscal 2025, so there was no public retail price; value was priced through trial progress, reimbursement hopes, and partner milestones. In this stage, the market pays for future proof, not unit cost.
| Metric | Fiscal 2025 |
|---|---|
| Approved commercial products | 0 |
| Retail product price | None |
| Monetization model | Milestones and collaboration fees |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.